Regeneron (REGN) Tops Q1 EPS by 89c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Reports First Quarter 2021 Financial and Operating Results
May 6, 2021 6:30 AM EDTTARRYTOWN, N.Y., May 6, 2021 /PRNewswire/ --
First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COVTM(1) increased 20% First quarter 2021 EYLEA® U.S. net sales increased 15% to $1.35 billion versus first quarter 2020 First quarter 2021 Dupixent® global net sales(2), which are recorded by Sanofi, increased 48% to $1.26 billion versus first quarter 2020 First quarter 2021 GAAP diluted EPS was $10.09 and non-GAAP diluted EPS(1) was $9.89 Three FDA approvals received: Libtayo® for first-line advanced non-small cell lung cancer (NSCLC) and advanced basal cell carcinoma (BCC),... More